IPO
Corxel plans SPAC merger with Amanat Acquisition to fund oral obesity drug CX11 through phase 3
Key Facts
Signal Type
IPO
Industry
Biotech
Companies
Corxel Pharmaceuticals, Amanat Acquisition, TCGX, Vincentage, TriGemX Bio
Date
Corxel Pharmaceuticals, a biotech focused on oral GLP-1 obesity drugs, agreed in principle to merge with SPAC Amanat Acquisition. The deal includes $75 million held by the SPAC plus $300 million in PIPE financing from top healthcare investors including RA Capital, NEA, SR One, and TCGX. The combined company will trade under a new name on the Nasdaq, targeted to close in the first half of 2026.
Corxel’s U.S. entity and its obesity assets are directly affected; the Shanghai-based parent retains rights to CX11 in Asia. Investors in the PIPE (TCGX, NEA, SR One, LifeSci Venture Partners, RA Capital) now have significant ownership stakes. Current and potential vendors supporting Phase 3 clinical development—such as CROs, eTMF providers, and clinical operations software vendors—will see immediate demand as enrollment kicks off in Q1 2026.
With $375 million in total cash, Corxel estimates its funding runway extends through 2029. Key implications:
Phase 3 enrollment initiation (expected Q1 2026) will be the next major milestone. Watch for FDA alignment on trial protocol—Corxel has already engaged the agency. Also monitor how the company differentiates CX11’s safety/efficacy profile in a crowded market, and whether the SPAC merger closes on schedule in H1 2026.
Source:
Fierce BiotechGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
